{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:56:22Z","timestamp":1791608182092,"version":"4.3.4"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-vascular endothelial growth factor (anti-VEGF) agents are the cornerstone therapy for retinal vascular diseases including neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. With patent expirations of ranibizumab and aflibercept, biosimilars have emerged as cost-effective alternatives. However, vitreoretinal specialists require consolidated evidence on regulatory standards, clinical equivalence, and practical implementation strategies to guide evidence-based integration of biosimilars into clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a narrative review of regulatory documents from the FDA, EMA, and NMPA, as well as Phase III clinical trials, real-world studies, and pharmacoeconomic analyses of approved ophthalmic anti-VEGF biosimilars. Literature searches were performed across PubMed, Embase, and regulatory databases from 2015 to 2025. Studies were included if they reported regulatory approval pathways, clinical efficacy and safety data, interchangeability studies, or pharmacoeconomic evaluations of anti-VEGF biosimilars in retinal diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Regulatory frameworks demonstrate rigorous biosimilarity assessment through comprehensive analytical characterization, preclinical evaluation, and clinical trials. Pivotal Phase III studies confirm therapeutic equivalence of approved biosimilars (including ranibizumab-nuna and aflibercept-abzv) with comparable visual acuity outcomes, safety profiles, and immunogenicity to originator products. Real-world evidence for ranibizumab biosimilars supports comparable outcomes to originators, while evidence for aflibercept biosimilars remains preliminary and warrants continued pharmacovigilance. Pharmacoeconomic analyses demonstrate 20\u201340% cost reduction compared to originators, offering substantial healthcare savings and improved patient access. Key implementation considerations include extrapolation principles, switching protocols, and clinic workflow integration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although real-world data for aflibercept biosimilars are currently limited, emerging evidence for ranibizumab biosimilars supports comparable outcomes. Approved anti-VEGF biosimilars represent safe, effective, and cost-saving alternatives for retinal diseases. With robust analytical and clinical evidence supporting biosimilarity, vitreoretinal specialists can confidently adopt these agents. Successful integration requires understanding of regulatory science, evidence-based switching protocols, and healthcare system collaborations to maximize patient benefits while maintaining treatment standards. Future research should focus on long-term outcomes, broader implementation studies, and pharmacovigilance monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00872-9","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T10:53:56Z","timestamp":1780138436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biosimilars of anti-VEGF agents in retinal diseases: a narrative review of regulatory, clinical, and pharmacoeconomic aspects"],"prefix":"10.1186","volume":"12","author":[{"given":"Yuan","family":"Zong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"1","key":"872_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","volume":"9","author":"Y Deng","year":"2022","unstructured":"Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, et al. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes & Dis. 2022;9(1):62\u201379. https:\/\/doi.org\/10.1016\/j.gendis.2021.02.009.","journal-title":"Genes & Dis"},{"key":"872_CR2","doi-asserted-by":"publisher","unstructured":"Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. JMCP. 2018;24(2\u2013a Suppl):S3\u2013s15. https:\/\/doi.org\/10.18553\/jmcp.2018.24.2-a.s3.","DOI":"10.18553\/jmcp.2018.24.2-a.s3"},{"issue":"3","key":"872_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556\u201364. https:\/\/doi.org\/10.2337\/dc11-1909.","journal-title":"Diabetes Care"},{"key":"872_CR4","doi-asserted-by":"publisher","unstructured":"Kapur M, Nirula S, Naik MP. Future of anti-VEGF: biosimilars and biobetters. Int J Retin Vitr. 2022;8(1). https:\/\/doi.org\/10.1186\/s40942-021-00343-3.","DOI":"10.1186\/s40942-021-00343-3"},{"key":"872_CR5","doi-asserted-by":"crossref","unstructured":"Zong Y, Miyagaki M, Yang M, Zhang J, Zou Y, Ohno-Matsui K, et al. Ophthalmic use of targeted biologics in the management of intraocular diseases: current and emerging therapies. Antibodies. 2024;13(4):86. https:\/\/www.mdpi.com\/2073-4468\/13\/4\/86.","DOI":"10.3390\/antib13040086"},{"issue":"8","key":"872_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14712598.2023.2247972","volume":"23","author":"M Calamia","year":"2023","unstructured":"Calamia M, Abraham I. The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries. Expert Opin Biol Ther. 2023;23(8):653\u201357. https:\/\/doi.org\/10.1080\/14712598.2023.2247972.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"872_CR7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40123-022-00488-w","volume":"11","author":"SM Hariprasad","year":"2022","unstructured":"Hariprasad SM, Gale RP, Weng CY, Ebbers HC, Rezk MF, Tadayoni R. An introduction to biosimilars for the treatment of retinal diseases: a narrative review. Ophthalmol Ther. 2022;11(3):959\u201382. https:\/\/doi.org\/10.1007\/s40123-022-00488-w.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"872_CR8","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s40123-023-00715-y","volume":"12","author":"Y Yanagi","year":"2023","unstructured":"Yanagi Y, Takahashi K, Iida T, Gomi F, Morii J, Kunikane E, et al. Cost-effectiveness analysis of ranibizumab biosimilar for neovascular age-related macular degeneration in Japan. Ophthalmol Ther. 2023;12(4):2005\u201321. https:\/\/doi.org\/10.1007\/s40123-023-00715-y.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"872_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/ceo.13706","volume":"48","author":"S Jackson","year":"2020","unstructured":"Jackson S, Stokes JP. Impact of out-of-pocket costs on patient initiation, adherence and per sistence rates for patients treated with anti-vascular endothelial gro wth factor medicines. Clin Exper Ophthalmol. 2020;48(4):477\u201385. https:\/\/doi.org\/10.1111\/ceo.13706.","journal-title":"Clin Exper Ophthalmol"},{"key":"872_CR10","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2147\/OPTH.S180393","volume":"12","author":"A Sharma","year":"2018","unstructured":"Sharma A, Reddy P, Kuppermann BD, Bandello F, Loewenstein A. Biosimilars in ophthalmology: \u201cis there a big change on the horizon?\u201d. OPTH. 2018;12:2137\u201343. https:\/\/doi.org\/10.2147\/OPTH.S180393.","journal-title":"OPTH"},{"issue":"6","key":"872_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-017-0717-1","volume":"77","author":"P Declerck","year":"2017","unstructured":"Declerck P, Danesi R, Petersel D, Jacobs I. The Language of biosimilars: clarification, Definitions, and regulator y aspects. Drugs. 2017;77(6):671\u201377. https:\/\/doi.org\/10.1007\/s40265-017-0717-1.","journal-title":"Drugs"},{"issue":"3","key":"872_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40259-022-00533-x","volume":"36","author":"P Kurki","year":"2022","unstructured":"Kurki P, Kang H-N, Ekman N, Knezevic I, Weise M, Wolff-Holz E. Regulatory evaluation of Biosimilars: refinement of principles based o n the scientific evidence and clinical experience. BioDrugs. 2022;36(3):359\u201371. https:\/\/doi.org\/10.1007\/s40259-022-00533-x.","journal-title":"BioDrugs"},{"issue":"3","key":"872_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40259-017-0218-5","volume":"31","author":"R Markus","year":"2017","unstructured":"Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: regulatory consid erations and building confidence for the healthcare community. BioDrugs. 2017;31(3):175\u201387. https:\/\/doi.org\/10.1007\/s40259-017-0218-5.","journal-title":"BioDrugs"},{"issue":"2","key":"872_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/ph17020235","volume":"17","author":"F Mascarenhas-Melo","year":"2024","unstructured":"Mascarenhas-Melo F, Diaz M, Gon\u00e7alves MBS, Vieira P, Bell V, Viana S, et al. An Overview of biosimilars\u2014development, quality, regulatory issues, and management in healthcare. Pharmaceuticals. 2024;17(2):235. https:\/\/doi.org\/10.3390\/ph17020235.","journal-title":"Pharmaceuticals"},{"issue":"12","key":"872_CR15","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1002\/bit.26438","volume":"114","author":"CF Kirchhoff","year":"2017","unstructured":"Kirchhoff CF, Wang XZM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment t ools. Biotech & Bioeng. 2017;114(12):2696\u2013705. https:\/\/doi.org\/10.1002\/bit.26438.","journal-title":"Biotech & Bioeng"},{"issue":"3","key":"872_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40259-022-00533-x","volume":"36","author":"P Kurki","year":"2022","unstructured":"Kurki P, Kang HN, Ekman N, Knezevic I, Weise M, Wolff-Holz E. Regulatory evaluation of Biosimilars: refinement of Principles based on the scientific evidence and clinical experience. BioDrugs. 2022;36(3):359\u201371.","journal-title":"BioDrugs"},{"key":"872_CR17","doi-asserted-by":"publisher","unstructured":"Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar des ign and production? Rheumatology. 2017;56(suppl_4):iv14\u201329. https:\/\/doi.org\/10.1093\/rheumatology\/kex278.","DOI":"10.1093\/rheumatology\/kex278"},{"issue":"17","key":"872_CR18","doi-asserted-by":"publisher","first-page":"9240","DOI":"10.3390\/ijms25179240","volume":"25","author":"SK Niazi","year":"2024","unstructured":"Niazi SK, Omarsdottir S. Lectin-based fluorescent comparison of glycan profile\u2014FDA Validation to expedite approval of biosimilars. IJMS. 2024;25(17):9240. https:\/\/doi.org\/10.3390\/ijms25179240.","journal-title":"IJMS"},{"issue":"6","key":"872_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40259-019-00377-y","volume":"33","author":"E Wolff-Holz","year":"2019","unstructured":"Wolff-Holz E, Tiitso K, Vleminckx C, Weise M. Evolution of the EU biosimilar framework: past and Future. BioDrugs. 2019;33(6):621\u201334. https:\/\/doi.org\/10.1007\/s40259-019-00377-y.","journal-title":"BioDrugs"},{"issue":"1","key":"872_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamaophthalmol.2020.5053","volume":"139","author":"SJ Woo","year":"2021","unstructured":"Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, et al. Efficacy and safety of a Proposed ranibizumab biosimilar product vs a Reference ranibizumab product for patients with neovascular age-related macular degeneration. JAMA Ophthalmol. 2021;139(1):68. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.5053.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"872_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/jamaophthalmol.2022.5403","volume":"141","author":"NM Bressler","year":"2023","unstructured":"Bressler NM, Kim T, Oh I, Russo P, Kim MY, Woo SJ. Immunogenicity with ranibizumab biosimilar SB11 (Byooviz) and Reference product Lucentis and association with efficacy, safety, and pharmacokinetics. JAMA Ophthalmol. 2023;141(2):117. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.5403.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"872_CR22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-017-0717-1","volume":"77","author":"P Declerck","year":"2017","unstructured":"Declerck P, Danesi R, Petersel D, Jacobs I. The Language of biosimilars: clarification, Definitions, and regulatory aspects. Drugs. 2017;77(6):671\u201377. https:\/\/doi.org\/10.1007\/s40265-017-0717-1.","journal-title":"Drugs"},{"issue":"3","key":"872_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2217\/fon-2018-0553","volume":"15","author":"T Schreitm\u00fcller","year":"2019","unstructured":"Schreitm\u00fcller T, Barton B, Zharkov A, Bakalos G. Comparative immunogenicity assessment of biosimilars. Future Oncol. 2019;15(3):319\u201329. https:\/\/doi.org\/10.2217\/fon-2018-0553.","journal-title":"Future Oncol"},{"issue":"5","key":"872_CR24","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s12325-021-01688-9","volume":"38","author":"A Afzali","year":"2021","unstructured":"Afzali A, Furtner D, Melsheimer R, Molloy PJ. The automatic substitution of biosimilars: definitions of interchangeability are not interchangeable. Adv Ther. 2021;38(5):2077\u201393. https:\/\/doi.org\/10.1007\/s12325-021-01688-9.","journal-title":"Adv Ther"},{"issue":"12","key":"872_CR25","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","volume":"42","author":"PK Kaiser","year":"2022","unstructured":"Kaiser PK, Schmitz-Valckenberg MS, Holz FG. Anti\u2013vascular endothelial growth factor biosimilars in ophthalmology. Retina. 2022;42(12):2243\u201350. https:\/\/doi.org\/10.1097\/IAE.0000000000003626.","journal-title":"Retina"},{"issue":"2","key":"872_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41433-022-02246-5","volume":"37","author":"A Sharma","year":"2023","unstructured":"Sharma A, Kondo M, Iwahashi C, Parachuri N, Kumar N, Bandello F, et al. Approved biosimilar ranibizumab\u2014a global update. Eye. 2023;37(2):200\u201302. https:\/\/doi.org\/10.1038\/s41433-022-02246-5.","journal-title":"Eye"},{"key":"872_CR27","unstructured":"Ranibizumab similar biologic launched in India 2015 Available from: https:\/\/www.gabionline.net\/biosimilars\/news\/Ranibizumab-similar-biologic-launched-in-India."},{"issue":"10","key":"872_CR28","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/s41433-024-03001-8","volume":"38","author":"A Sharma","year":"2024","unstructured":"Sharma A, Kumar N, Parachuri N, Bandello F, Loewenstein A, Kuppermann BD. Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs. Eye (Lond). 2024;38(10):1796\u201398.","journal-title":"Eye (Lond)"},{"key":"872_CR29","unstructured":"United kingdom medicines and healthcare products regulatory Agency (MHRA) grants marketing authorization for FYB201, Formycon\u2019s biosimilar for Lucentis\u00ae1, to be commercialized by teva as ONGAVIA\u00ae - Formycon AG, 2022 updated 2022\/05\/17. Available from: https:\/\/www.formycon.com\/en\/blog\/press-release\/united-kingdom-medicines-and-healthcare-products-regulatory-agency-mhra-grants-marketing-authorization-for-fyb201-formycons-biosimilar-for-lucentis1-to-be-commercialized-by-teva-as-ongavia\/."},{"key":"872_CR30","unstructured":"Coherus BioSciences I. FDA approves coherus\u2019 CIMERLI\u2122 (ranibizumab-eqrn) as the first and only interchangeable biosimilar to Lucentis\u00ae for all five indications, with 12 months of interchangeability exclusivity. Coherus oncology. 2022 Available from: https:\/\/investors.coherus.com\/news-releases\/news-release-details\/fda-approves-coherus-cimerlitm-ranibizumab-eqrn-first-and-only."},{"key":"872_CR31","unstructured":"Formycon AG. European Commission approves FYB201\/Ranivisio\u00ae1 (Ranivisio - ranibizumab), a biosimilar to Lucentis\u00ae2: Formycon AG; 2022 updated 2022\/08\/29. Available from: https:\/\/www.formycon.com\/en\/blog\/press-release\/european-commission-approves-fyb201-ranivisio1-ranivisio-ranibizumab-a-biosimilar-to-lucentis2\/."},{"key":"872_CR32","unstructured":"Biogen I. FDA approves Samsung Bioepis and Biogen\u2019s BYOOVIZ\u2122 (SB11). Lucentis\u00ae Biosimilar (Ranibizumab-Nuna). Biogen. 2021, 2021\/09\/20."},{"key":"872_CR33","unstructured":"Ranibizumab biosimilar (Byooviz) gains EU marketing authorization 2021 Available from: https:\/\/www.centerforbiosimilars.com\/view\/samsung-bioepis-byooviz-gains-ema-marketing-authorization."},{"key":"872_CR34","unstructured":"H-S L. Traditional Korean drugmakers advance into biosimilar market. KBR. 2023. https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=20339."},{"key":"872_CR35","unstructured":"Kidswell Bio C. Announcement of approval of additional indication of ranibizumab BS (excerpt from Japanese version): Kidswell Bio Corporation; 2023 updated 2023\/09\/27. Available from: https:\/\/www.kidswellbio.com\/Portals\/0\/resources\/pdf\/en\/20230927-02.pdf."},{"issue":"2","key":"872_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.17749\/2070-4909\/farmakoekonomika.2025.313","volume":"18","author":"FV Gorkavenko","year":"2025","unstructured":"Gorkavenko FV, Goryachev AB, Ashikhmina OV, Fedyaev DV, Ignateva NV, Smolyarchuk EA, et al. Marketing analysis of the Russian pharmaceutical market for treatment of neovascular age-related macular degeneration. Farmako\u00e8konomika. 2025;18(2):184\u201398. https:\/\/doi.org\/10.17749\/2070-4909\/farmakoekonomika.2025.313.","journal-title":"Farmako\u00e8konomika"},{"key":"872_CR37","unstructured":"National Medical Products A. Drug Approval Certificate Delivery Information. 2024 Available from: https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20240819150923195.html. August 19, 2024: National Medical Products Administration."},{"key":"872_CR38","unstructured":"Rimmyrah | European medicines Agency (EMA) 2024 updated 2025\/10\/24. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rimmyrah#ema-inpage-item-product-info."},{"issue":"6","key":"872_CR39","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14712598.2025.2506445","volume":"25","author":"A Sharma","year":"2025","unstructured":"Sharma A, Regillo CD, Nicholson L, Kumar N, Parachuri N, Wakabayashi T, et al. The conundrum of abundance: challenges of having too many biosimilars. Expert Opin Biol Ther. 2025;25(6):573\u201376. https:\/\/doi.org\/10.1080\/14712598.2025.2506445.","journal-title":"Expert Opin Biol Ther"},{"key":"872_CR40","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2147\/OPTH.S407219","volume":"17","author":"D Chakraborty","year":"2023","unstructured":"Chakraborty D, Mondal S, Boral S, Das A, Sinha TK, Majumdar S, et al. Biosimilar versus InnovAtor molecule of RAnibizumab in neovascular age -related MaCular DEgeneration (The BALANCE Trial): real-world evidence. OPTH. 2023;17:1067\u201376. https:\/\/doi.org\/10.2147\/OPTH.S407219.","journal-title":"OPTH"},{"issue":"1","key":"872_CR41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","volume":"129","author":"FG Holz","year":"2022","unstructured":"Holz FG, Oleksy P, Ricci F, Kaiser PK, Kiefer J, Schmitz-Valckenberg S. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2022;129(1):54\u201363. https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.031.","journal-title":"Ophthalmology"},{"issue":"null","key":"872_CR42","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.2147\/OPTH.S500912","volume":"18","author":"D Chakraborty","year":"2024","unstructured":"Chakraborty D, Sinha TK, Maiti A, Boral SK, Das A, Mondal S, et al. Transitioning from aflibercept to biosimilar ranibizumab in diabetic macular edema (DME): (The TRANSFORM-DME trial) a multicenter observational study. OPTH. 2024;18(null):3449\u201356. https:\/\/doi.org\/10.2147\/OPTH.S500912. https:\/\/www.tandfonline.com\/doi\/abs\/10.2147\/OPTH.S500912.","journal-title":"OPTH"},{"issue":"3","key":"872_CR43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40123-020-00277-3","volume":"9","author":"S Sharma","year":"2020","unstructured":"Sharma S, Anandkumar MB, Jain S, Murthy H, Murlidhar NS, Hirawat RS, et al. A multicenter, retrospective study (RE-ENACT 2) on Razumab\u2122 (world\u2019s first biosimilar ranibizumab) in retinal vein occlusion. Ophthalmol Ther. 2020;9(3):625\u201339. https:\/\/doi.org\/10.1007\/s40123-020-00277-3.","journal-title":"Ophthalmol Ther"},{"key":"872_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ajo.2020.11.017","volume":"224","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Biosimilars for retinal diseases: an update. Am J Ophthalmol. 2021;224:36\u201342.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"872_CR45","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/bjophthalmol-2021-319637","volume":"107","author":"NM Bressler","year":"2023","unstructured":"Bressler NM, Veith M, Hamouz J, Ernest J, Zalewski D, Studni\u010dka J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-relate d macular degeneration: 1-year phase III randomised clinical trial out comes. Br J Ophthalmol. 2023;107(3):384\u201391. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319637.","journal-title":"Br J Ophthalmol"},{"key":"872_CR46","unstructured":"Drug E C, Research. FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions: U.S. Food Drug Adm. 2024 updated 2024\/08\/09\/2025\/10\/24. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-interchangeable-biosimilars-eylea-treat-macular-degeneration-and-other-eye."},{"key":"872_CR47","unstructured":"Yesafili | European Medicines Agency. 2023 updated 2023\/09\/15\/. 6: Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yesafili (EMA): European Medicines Agency."},{"key":"872_CR48","unstructured":"Bioblast E. Approval alert: first aflibercept biosimilar approved in Korea, as Samsung Bioepis\u2019 Afilivu\u00ae gets the green light 2024 Available from: https:\/\/www.pearceip.law\/2024\/02\/26\/approval-alert-first-aflibercept-biosimilar-approved-in-korea-as-samsung-bioepis-afilivu-gets-the-green-light\/."},{"key":"872_CR49","unstructured":"Opuviz | European Medicines Agency. 2024 updated 2024\/09\/20\/. 2025\/07\/16\/: Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opuviz (EMA): European Medicines Agency."},{"key":"872_CR50","unstructured":"Ga BIO. FDA approves third aflibercept biosimilar ahzantive 2024 updated 2024\/08\/13\/. Available from: https:\/\/www.gabionline.net\/biosimilars\/news\/fda-approves-third-aflibercept-biosimilar-ahzantive."},{"key":"872_CR51","unstructured":"Baiama | European Medicines Agency. 2025 updated 2025\/10\/15. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/baiama (EMA): European Medicines Agency (EMA)."},{"key":"872_CR52","unstructured":"Anti-VEGF injection for retinal disease - PAVBLU\u2122 (aflibercept-ayyh) 2025 Available from: https:\/\/www.pavblu.com\/."},{"key":"872_CR53","unstructured":"Pavblu | European medicines Agency (EMA) 2025 updated 2025\/06\/26\/. Revision. 1: Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pavblu."},{"key":"872_CR54","unstructured":"Jeremias S. FDA approves biosimilar enzeevu for eye conditions 2024 updated 2024\/08\/12. Available from: https:\/\/www.centerforbiosimilars.com\/view\/fda-approves-biosimilar-enzeevu-for-eye-conditions."},{"key":"872_CR55","unstructured":"Afqlir | European medicines Agency (EMA) 2024 2025\/07\/23\/: Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/afqlir."},{"key":"872_CR56","unstructured":"Bioblast E. Approval alert: Celltrion\u2019s aflibercept biosimilar approved in Korea 2024 Available from: https:\/\/www.pearceip.law\/2024\/05\/30\/approval-alert-celltrions-aflibercept-biosimilar-approved-in-korea\/."},{"key":"872_CR57","unstructured":"Eydenzelt | European medicines Agency (EMA): European medicines Agency (EMA); 2025 updated 2025\/06\/06. Revision. 2: Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eydenzelt."},{"key":"872_CR58","unstructured":"Celltrion Usa INC. Highlights of prescribing Information: EYDENZELT\u00ae (aflibercept-boav). 2025 updated 2025-10. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761377s000lbl.pdf Injection: CELLTRION USA INC."},{"key":"872_CR59","doi-asserted-by":"publisher","unstructured":"Zhai G, Liu N, Wang S, Zhang X. Comparative efficacy of intravitreal aflibercept biosimilar QL1207 versus reference aflibercept in the treatment of diabetic macular edema. Front. Med. 2025;12:- 2025. https:\/\/doi.org\/10.3389\/fmed.2025.1662735.","DOI":"10.3389\/fmed.2025.1662735"},{"key":"872_CR60","unstructured":"Alteogen I. Alteogen receives Ministry of Food and Drug safety (MFDS) approval for Tergase\u00ae. 2024 updated 2024 July 8. Available from: https:\/\/www.prnewswire.com\/news-releases\/alteogen-receives-ministry-of-food-and-drug-safety-mfds-approval-for-tergase-302190530.html: PR Newswire."},{"key":"872_CR61","unstructured":"Eydenzelt | European Medicines Agency (EMA): European Medicines Agency (EMA); 2025 updated 2025\/06\/06. Revision 2: Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eyluxvi."},{"issue":"5","key":"872_CR62","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41433-023-02813-4","volume":"38","author":"A Sharma","year":"2024","unstructured":"Sharma A, Loewenstein A, Kumar N, Parachuri N, Bandello F, Kuppermann BD. Aflibercept biosimilars \u2013 update on the development progress. Eye. 2024;38(5):824\u201325. https:\/\/doi.org\/10.1038\/s41433-023-02813-4.","journal-title":"Eye"},{"issue":"17","key":"872_CR63","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.3390\/ijms25179184","volume":"25","author":"Y Zong","year":"2024","unstructured":"Zong Y, Kamoi K, Miyagaki M, Zhang J, Yang M, Zou Y, et al. Applications of biological therapy for latent infections: benefits and risks. IJMS. 2024;25(17):9184. https:\/\/doi.org\/10.3390\/ijms25179184.","journal-title":"IJMS"},{"issue":"20","key":"872_CR64","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897\u2013908.","journal-title":"N Engl J Med"},{"issue":"4","key":"872_CR65","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.survophthal.2024.03.009","volume":"69","author":"NM Bressler","year":"2024","unstructured":"Bressler NM, Kaiser PK, Do DV, Nguyen QD, Park KH, Woo SJ, et al. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: a review. Surv Ophthalmol. 2024;69(4):521\u201338. https:\/\/doi.org\/10.1016\/j.survophthal.2024.03.009.","journal-title":"Surv Ophthalmol"},{"issue":"null","key":"872_CR66","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2147\/OPTH.S180393","volume":"12","author":"A Sharma","year":"2018","unstructured":"Sharma A, Reddy P, Kuppermann BD, Bandello F, Loewenstein A. Biosimilars in ophthalmology: \u201cis there a big change on the horizon?\u201d. OPTH. 2018;12(null):2137\u201343. https:\/\/doi.org\/10.2147\/OPTH.S180393. https:\/\/www.tandfonline.com\/doi\/abs\/10.2147\/OPTH.S180393.","journal-title":"OPTH"},{"key":"872_CR67","unstructured":"Outlook Therapeutics I. Outlook Therapeutics\u00ae receives European commission marketing authorization for LYTENAVA\u2122 (bevacizumab gamma) for the treatment of wet AMD, 2024 updated 2024-05-28. Available from: https:\/\/ir.outlooktherapeutics.com\/news-releases\/news-release-details\/outlook-therapeuticsr-receives-european-commission-marketing\/."},{"issue":"null","key":"872_CR68","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.2147\/OPTH.S473329","volume":"18","author":"S Chakraborty","year":"2024","unstructured":"Chakraborty S, Sheth JU. Efficacy and safety of an Indian bevacizumab BIOSimilar (BEVATAS) for retinal vein occlusion (BIOS-RVO study). OPTH. 2024;18(null):2865\u201371. https:\/\/doi.org\/10.2147\/OPTH.S473329. https:\/\/www.tandfonline.com\/doi\/abs\/10.2147\/OPTH.S473329.","journal-title":"OPTH"},{"issue":"5","key":"872_CR69","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/ceo.14515","volume":"53","author":"H Wang","year":"2025","unstructured":"Wang H, Bahrami B, Huang S, Tahmasebi Sarvestani M, Cugati S, Lake S, et al. Safety of an intravitreal bevacizumab biosimilar (MVASI). Clin Exper Ophthalmol. 2025;53(5):523\u201328. https:\/\/doi.org\/10.1111\/ceo.14515.","journal-title":"Clin Exper Ophthalmol"},{"issue":"3","key":"872_CR70","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1089\/jop.2022.0059","volume":"39","author":"MA Peraza","year":"2023","unstructured":"Peraza MA, Hurst S, Huang W, Buetow BS, Lickteig AJ, Lavach JD, et al. Ocular safety and Toxicokinetics of bevacizumab-bvzr (Zirabev), a bevacizumab biosimilar, administered to cynomolgus monkeys by intravitreal injection. J Ocul Pharmacol Th. 2023;39(3):215\u201324. https:\/\/doi.org\/10.1089\/jop.2022.0059.","journal-title":"J Ocul Pharmacol Th"},{"key":"872_CR71","doi-asserted-by":"publisher","unstructured":"Yoon CK, Oh J, Bae K, Park UC, Yu K-S, Yu HG. Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pr o re nata treatment regimen in neovascular age-related macular degener ation: a phase 3 randomized clinical trial. PLoS One. 2022;17(11):e0275611. https:\/\/doi.org\/10.1371\/journal.pone.0275611.","DOI":"10.1371\/journal.pone.0275611."},{"key":"872_CR72","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.2147\/OPTH.S307746","volume":"15","author":"P Apsangikar","year":"2021","unstructured":"Apsangikar P, Ghadge P, Naik M, Nair S, Payghan PR. Randomised, double-blind, comparative clinical study of new ranibizumab biosimilar in neovascular (wet) age-related macular degeneration. OPTH. 2021;15:3087\u201395. https:\/\/doi.org\/10.2147\/OPTH.S307746.","journal-title":"OPTH"},{"key":"872_CR73","doi-asserted-by":"publisher","unstructured":"Hatamnejad A, Dadak R, Orr S, Wykoff C, Choudhry N. Systematic review of efficacy and meta-analysis of safety of ranibizum ab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol. 2023;8(1):e001205. https:\/\/doi.org\/10.1136\/bmjophth-2022-001205.","DOI":"10.1136\/bmjophth-2022-001205"},{"issue":"7","key":"872_CR74","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","volume":"141","author":"SJ Woo","year":"2023","unstructured":"Woo SJ, Bradvica M, Vajas A, Sagong M, Ernest J, Studnicka J, et al. Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: a phase 3 randomized clinical trial. JAMA Ophthalmol. 2023;141(7):668\u201376. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2260.","journal-title":"JAMA Ophthalmol"},{"key":"872_CR75","unstructured":"Food US, Administration D. Center for Drug E, Research. Biosimilar multidisciplinary evaluation and review for BLA 761378: FYB203 (aflibercept-mrbb) Proposed biosimilar to US-licensed Eylea [BLA 761378]. 2024 updated 2024-06-28. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/761378Orig1s000MultidisciplineR.pdf."},{"issue":"2","key":"872_CR76","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.oret.2025.07.015","volume":"10","author":"S Friedman","year":"2026","unstructured":"Friedman S, London N, Hamouz J, Ker\u00e9nyi \u00c1, Papp A, Pregun T, et al. Randomized trial of biosimilar ABP 938 compared with Reference aflibercept in adults with neovascular age-related macular degeneration. Ophthalmol Retina. 2026;10(2):152\u201364. https:\/\/doi.org\/10.1016\/j.oret.2025.07.015. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2468653025003513.","journal-title":"Ophthalmol Retina"},{"issue":"10","key":"872_CR77","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1097\/IAE.0000000000004174","volume":"44","author":"AF Bordon","year":"2024","unstructured":"Bordon AF, Kaiser PK, Wolf A, Cen L, Heyn J, Urosevic D, et al. Efficacy and safety of the proposed biosimilar aflibercept, SDZ-AFL, in patients with neovascular age-related macular degeneration: 52-week results from the phase 3 mylight study. Retina. 2024;44(10):1704\u201313. https:\/\/doi.org\/10.1097\/IAE.0000000000004174.","journal-title":"Retina"},{"issue":"9","key":"872_CR78","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40261-025-01458-3","volume":"45","author":"YY Syed","year":"2025","unstructured":"Syed YY. SDZ-AFL: an aflibercept biosimilar. Clin Drug Investig. 2025;45(9):677\u201380. https:\/\/doi.org\/10.1007\/s40261-025-01458-3.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"872_CR79","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40123-023-00836-4","volume":"13","author":"B Li","year":"2024","unstructured":"Li B, Fan K, Zhang T, Wu Z, Zeng S, Zhao M, et al. Efficacy and safety of biosimilar QL1207 vs. The Reference aflibercept for patients with neovascular age-related macular degeneration: a randomized phase 3 trial. Ophthalmol Ther. 2024;13(1):353\u201366. https:\/\/doi.org\/10.1007\/s40123-023-00836-4.","journal-title":"Ophthalmol Ther"},{"issue":"10","key":"872_CR80","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamaophthalmol.2024.3458","volume":"142","author":"SB Bressler","year":"2024","unstructured":"Bressler SB, Barve A, Ganapathi PC, Beckmann K, Apte RS, Marcus DM, et al. Aflibercept biosimilar MYL-1701P vs Reference aflibercept in Diabetic macular edema: the INSIGHT randomized clinical trial. JAMA Ophthalmol. 2024;142(10):952\u201360. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.3458.","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"872_CR81","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s40123-025-01197-w","volume":"14","author":"DM Brown","year":"2025","unstructured":"Brown DM, Wolf S, Veselovsky M, Veith M, Papp A, Mange S, et al. Long-term efficacy and safety of CT-P42 in patients with Diabetic macular edema: 52-week results from a phase 3 randomized clinical trial. Ophthalmol Ther. 2025;14(11):2769\u201383. https:\/\/doi.org\/10.1007\/s40123-025-01197-w.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"872_CR82","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40942-021-00293-w","volume":"7","author":"S Sharma","year":"2021","unstructured":"Sharma S, Gupta V, Maiti A, Natesh S, Saxena S, Dave V, et al. Safety and efficacy of Razumab\u2122 (world\u2019s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study. Int J Retin Vitr. 2021;7(1):24. https:\/\/doi.org\/10.1186\/s40942-021-00293-w.","journal-title":"Int J Retin Vitr"},{"issue":"1","key":"872_CR83","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40123-021-00416-4","volume":"11","author":"D Ratra","year":"2022","unstructured":"Ratra D, Roy K, Giridhar S, Madaan S, Bhende P, Bhende M, et al. Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation. Ophthalmol Ther. 2022;11(1):135\u201349. https:\/\/doi.org\/10.1007\/s40123-021-00416-4.","journal-title":"Ophthalmol Ther"},{"key":"872_CR84","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.2147\/OPTH.S549744","volume":"19","author":"D Chakraborty","year":"2025","unstructured":"Chakraborty D, Sinha TK, Sinha S, Biswas RK, Maiti A, Nandi K, et al. Biosimilar versus innovator ranibizumab in myopic CNVM: comparative real-world outcomes- the BRIM study. OPTH. 2025;19:3741\u201347. https:\/\/doi.org\/10.2147\/OPTH.S549744.","journal-title":"OPTH"},{"key":"872_CR85","doi-asserted-by":"crossref","unstructured":"Bas TG. Innovative formulation strategies for biosimilars: trends focused on buffer-free systems, safety, regulatory alignment, and intellectual property challenges. Pharmaceuticals. 2025;18(6):908. https:\/\/www.mdpi.com\/1424-8247\/18\/6\/908.","DOI":"10.3390\/ph18060908"},{"issue":"1","key":"872_CR86","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5639\/gabij.2024.1301.006","volume":"13","author":"MS Reilly","year":"2024","unstructured":"Reilly MS. Preserve the US interchangeable standard that has helped drive physici an and patient confidence in biosimilars. GaBI J. 2024;13(1):34\u201336. https:\/\/doi.org\/10.5639\/gabij.2024.1301.006.","journal-title":"GaBI J"},{"key":"872_CR87","doi-asserted-by":"publisher","first-page":"107224","DOI":"10.1016\/j.ejps.2025.107224","volume":"213","author":"AB Iskit","year":"2025","unstructured":"Iskit AB. Biosimilars and interchangeability: regulatory, scientific, and global perspectives. Eur J Pharm Sci. 2025;213:107224. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0928098725002234.","journal-title":"Eur J Pharm Sci"},{"issue":"16","key":"872_CR88","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s40265-021-01610-1","volume":"81","author":"E Mysler","year":"2021","unstructured":"Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, et al. Biosimilar-to-biosimilar switching: what is the rationale and current experience? Drugs. 2021;81(16):1859\u201379. https:\/\/doi.org\/10.1007\/s40265-021-01610-1.","journal-title":"Drugs"},{"key":"872_CR89","doi-asserted-by":"publisher","unstructured":"Herndon TM, Ausin C, Brahme NN, Schrieber SJ, Luo M, Andrada FC, et al. Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis. PLoS One. 2023;18(10):e0292231. https:\/\/doi.org\/10.1371\/journal.pone.0292231.","DOI":"10.1371\/journal.pone.0292231"},{"issue":"6","key":"872_CR90","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41433-019-0745-z","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Hafeez Faridi M, Kumar N, Parachuri N, Sharma R, Kuppermann BD, et al. Immunogenicity and efficacy after switching from original ranibizumab to a ranibizumab biosimilar: real-world data. Eye. 2020;34(6):1008\u201309. https:\/\/doi.org\/10.1038\/s41433-019-0745-z.","journal-title":"Eye"},{"issue":"6","key":"872_CR91","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3390\/ph18060908","volume":"18","author":"TG Bas","year":"2025","unstructured":"Bas TG. Innovative formulation strategies for biosimilars: trends focused on buffer-Free systems, safety, regulatory Alignment, and Intellectual Property challenges. Pharmaceuticals (Basel). 2025;18(6):908. https:\/\/doi.org\/10.3390\/ph18060908.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"872_CR92","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","volume":"7","author":"WJ Anderson","year":"2021","unstructured":"Anderson WJ, da Cruz NFS, Lima LH, Emerson GG, Rodrigues EB, Melo GB. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retin Vitr. 2021;7(1):37. https:\/\/doi.org\/10.1186\/s40942-021-00307-7.","journal-title":"Int J Retin Vitr"},{"issue":"2","key":"872_CR93","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41433-023-02698-3","volume":"38","author":"A Sharma","year":"2024","unstructured":"Sharma A, Loewenstein A, Parachuri N, Kumar N, Rasal A, Bandello F, et al. Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge? Eye. 2024;38(2):244\u201345. https:\/\/doi.org\/10.1038\/s41433-023-02698-3.","journal-title":"Eye"},{"issue":"2","key":"872_CR94","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/14737167.2023.2297926","volume":"24","author":"J Mestre-Ferrandiz","year":"2024","unstructured":"Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, et al. Capturing the holistic value of biosimilars in Europe \u2013 part 1: a historical perspective. Expert Rev Pharmacoeconomics & Outcomes Res. 2024;24(2):237\u201350. https:\/\/doi.org\/10.1080\/14737167.2023.2297926.","journal-title":"Expert Rev Pharmacoeconomics & Outcomes Res"},{"key":"872_CR95","doi-asserted-by":"publisher","unstructured":"Chen H-H, Yemeke T, Ozawa S. Reduction of biologic pricing following biosimilar introduction: analysis across 57 countries and regions, 2012\u201319. PLoS One. 2024;19(6):e0304851. https:\/\/doi.org\/10.1371\/journal.pone.0304851.","DOI":"10.1371\/journal.pone.0304851"},{"key":"872_CR96","doi-asserted-by":"crossref","unstructured":"G S, Kumar S, K R. The biosimilar revolution: assessing the European Union\u2019s approach to biosimilarity, interchangeability, patient access, and its market analysis. Cureus. 2024;16(8):e68103.","DOI":"10.7759\/cureus.68103"},{"issue":"11","key":"872_CR97","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1377\/hlthaff.2024.00366","volume":"43","author":"J Jhang","year":"2024","unstructured":"Jhang J, Brennan TA. Evidence that regulatory and market forces are driving adoption of Bio similars: article examines evidence that regulatory and market forces are driving adoption of biosimilars. Health Aff (Millwood). 2024;43(11):1553\u201360. https:\/\/doi.org\/10.1377\/hlthaff.2024.00366.","journal-title":"Health Aff (Millwood)"},{"key":"872_CR98","doi-asserted-by":"publisher","unstructured":"Horn DM, Alpert AE, Duggan MG, Garcia NA, Jacobson M. Biosimilar competition and payments in Medicare: the case of trastuzum ab. JCO Oncol Pract. 2023;19(4):e476\u201383. https:\/\/doi.org\/10.1200\/OP.22.00639.","DOI":"10.1200\/OP.22.00639"},{"issue":"9","key":"872_CR99","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.18553\/jmcp.2021.27.9.1260","volume":"27","author":"A Almony","year":"2021","unstructured":"Almony A, Keyloun KR, Shah-Manek B, Multani JK, McGuiness CB, Chen C-C, et al. Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis. JMCP. 2021;27(9):1260\u201372. https:\/\/doi.org\/10.18553\/jmcp.2021.27.9.1260.","journal-title":"JMCP"},{"issue":"10","key":"872_CR100","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1007\/s10792-021-01906-x","volume":"41","author":"JM Ruiz-Moreno","year":"2021","unstructured":"Ruiz-Moreno JM, Arias L, Abraldes MJ, Montero J, Udaondo P. The Rsg. Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study. Int Ophthalmol. 2021;41(10):3427\u201336. https:\/\/doi.org\/10.1007\/s10792-021-01906-x.","journal-title":"Int Ophthalmol"},{"key":"872_CR101","unstructured":"Grand View R. Age-related macular degeneration market Size report, 2030: grand view Research; 2024 updated 2024\/09\/\/. Available from: https:\/\/www.grandviewresearch.com\/industry-analysis\/age-related-macular-degeneration-market-report."},{"key":"872_CR102","unstructured":"Group I. Diabetic macular edema market Size to reach USD 7.5 billion by 2034, impelled by growing Diabetic individuals. BioSpace. 2024, 2024\/08\/02."},{"key":"872_CR103","unstructured":"Proliferative Diabetic retinopathy market Size, growth 2025 - 2030: mordor intelligence; Available from: https:\/\/www.mordorintelligence.com\/industry-reports\/proliferative-diabetic-retinopathy-market."},{"key":"872_CR104","unstructured":"Izzio K. Analysis of the utilization of vegfinhibitors in rhode Island and in medicare part B nationally. 2025."},{"issue":"7","key":"872_CR105","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/14712598.2024.2350440","volume":"24","author":"R V\u00e1zquez-S\u00e1nchez","year":"2024","unstructured":"V\u00e1zquez-S\u00e1nchez R, Navarro-D\u00e1vila M, Herr\u00e1iz ER, Merino-Boh\u00f3rquez V, Borr\u00e1s-Blasco J, Onteniente-Gonz\u00e1lez A, et al. Biosimilars and access to biologic therapy in immune-mediated diseases. Expert Opin Biol Ther. 2024;24(7):647\u201353. https:\/\/doi.org\/10.1080\/14712598.2024.2350440.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"872_CR106","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1007\/s40123-024-01011-z","volume":"13","author":"Y Yanagi","year":"2024","unstructured":"Yanagi Y, Takahashi K, Iida T, Gomi F, Onishi H, Morii J, et al. Cost-effectiveness analysis of ranibizumab biosimilar for neovascular age-related macular degeneration and its subtypes from the societal and patient perspectives in Japan. Ophthalmol Ther. 2024;13(10):2629\u201344. https:\/\/doi.org\/10.1007\/s40123-024-01011-z.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"872_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25259\/IHOPEJO_1_2024","volume":"3","author":"R Narayanan","year":"2024","unstructured":"Narayanan R, Sheng Y. Significant reduction in the cost of care for retinal diseases in India due to the approval of biosimilars: lessons for health systems. IHOPEJO. 2024;3(1):1\u20132. https:\/\/doi.org\/10.25259\/IHOPEJO_1_2024.","journal-title":"IHOPEJO"},{"issue":"S1","key":"872_CR108","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1017\/jme.2023.112","volume":"51","author":"E Ortiz-Prado","year":"2023","unstructured":"Ortiz-Prado E, Izquierdo-Condoy JS, Vasconez-Gonz\u00e1lez JE, D\u00e1vila G, Correa T, Fern\u00e1ndez-Naranjo R. The pharmaceutical market for biological products in Latin America: a comprehensive analysis of regional sales data. J Law Med Ethics. 2023;51(S1):39\u201361. https:\/\/doi.org\/10.1017\/jme.2023.112.","journal-title":"J Law Med Ethics"},{"key":"872_CR109","volume-title":"Biosimilar coding and reimbursement under Medicare Part B","author":"C Stomberg","year":"2017","unstructured":"Stomberg C, Wolfert B, Manning R. Biosimilar coding and reimbursement under Medicare Part B. Washington, DC: Bates White Economic Consulting; 2017."},{"issue":"9","key":"872_CR110","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.ophtha.2023.04.019","volume":"130","author":"C Zhang","year":"2023","unstructured":"Zhang C, Friedman S, Mruthyunjaya P, Parikh R. The biosimilar Paradox: how anti-vascular endothelial growth factor biosimilars could increase patient and overall Health care costs. Ophthalmology. 2023;130(9):966\u201372. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0161642023002956.","journal-title":"Ophthalmology"},{"issue":"1","key":"872_CR111","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3201\/eid2101.141040","volume":"21","author":"LS Edison","year":"2015","unstructured":"Edison LS, Dishman HO, Tobin-D\u2019Angelo MJ, Allen CR, Guh AY, Drenzek CL. Endophthalmitis outbreak associated with repackaged bevacizumab. Emerg Infect Dis. 2015;21(1):171\u201373. https:\/\/doi.org\/10.3201\/eid2101.141040.","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"872_CR112","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/10826068.2021.1876729","volume":"51","author":"AS Rathore","year":"2021","unstructured":"Rathore AS, Bhargava A. Regulatory considerations in biosimilars: Latin America region. Prep Biochem Biotechnol. 2021;51(2):201\u201306. https:\/\/doi.org\/10.1080\/10826068.2021.1876729.","journal-title":"Prep Biochem Biotechnol"},{"issue":"6","key":"872_CR113","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/14712598.2025.2507173","volume":"25","author":"R Schaffel","year":"2025","unstructured":"Schaffel R, Cornes P, Espinoza MA, G\u00f3mez-Almaguer D, Maiolino A, Freire D, et al. The potential role of biosimilars in healthcare sustainability in Latin America. Expert Opin Biol Ther. 2025;25(6):633\u201347. https:\/\/doi.org\/10.1080\/14712598.2025.2507173.","journal-title":"Expert Opin Biol Ther"},{"issue":"10432","key":"872_CR114","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik J-F, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673624000631.","journal-title":"Lancet"},{"issue":"10326","key":"872_CR115","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"issue":"8","key":"872_CR116","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/14712598.2023.2176218","volume":"23","author":"A Sharma","year":"2023","unstructured":"Sharma A, Holz FG, Regillo CD, Freund KB, Sarraf D, Khanani AM, et al. Biosimilars for retinal diseases: United States-europe awareness survey (Bio-USER \u2013 survey). Expert Opin Biol Ther. 2023;23(8):851\u201359. https:\/\/doi.org\/10.1080\/14712598.2023.2176218.","journal-title":"Expert Opin Biol Ther"},{"issue":"16","key":"872_CR117","doi-asserted-by":"publisher","first-page":"5800","DOI":"10.3390\/ijerph17165800","volume":"17","author":"V Halimi","year":"2020","unstructured":"Halimi V, Daci A, Ancevska Netkovska K, Suturkova L, Babar ZUD, Grozdanova A. Clinical and regulatory concerns of Biosimilars: a review of literature. IJERPH. 2020;17(16):5800. https:\/\/www.mdpi.com\/1660-4601\/17\/16\/5800.","journal-title":"IJERPH"},{"key":"872_CR118","doi-asserted-by":"crossref","unstructured":"Colloca L, Panaccione R, Murphy TK. The clinical implications of nocebo effects for biosimilar therapy. Front Pharmacol. 2019;10-2019. https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2019.01372.","DOI":"10.3389\/fphar.2019.01372"},{"key":"872_CR119","doi-asserted-by":"publisher","unstructured":"Abitbol V, Benkhalifa S, Habauzit C, Marotte H. Navigating adalimumab biosimilars: an expert opinion. J Comp Eff Res. 2023;12(11). https:\/\/doi.org\/10.57264\/cer-2023-0117.","DOI":"10.57264\/cer-2023-0117."},{"issue":"3","key":"872_CR120","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/apt.14453","volume":"47","author":"EMH Schmitz","year":"2018","unstructured":"Schmitz EMH, Boekema PJ, Straathof JWA, van Renswouw DC, Brunsveld L, Scharnhorst V, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2018;47(3):356\u201363. https:\/\/doi.org\/10.1111\/apt.14453.","journal-title":"Aliment. Pharmacol. Ther"},{"issue":"5","key":"872_CR121","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jbspin.2017.10.003","volume":"85","author":"M Scherlinger","year":"2018","unstructured":"Scherlinger M, Germain V, Labadie C, Barnetche T, Truchetet ME, Bannwarth B, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine. 2018;85(5):561\u201367. https:\/\/doi.org\/10.1016\/j.jbspin.2017.10.003.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"872_CR122","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.30574\/ijsra.2024.13.2.2342","volume":"13","author":"GR Balaprabha","year":"2024","unstructured":"Balaprabha GR, Kondapalli S, Pochampally L, Reddy TA, Rao TR. Interchangeable biosimilars: a new era in healthcare system. Int J Sci Res Arch. 2024;13(2):3763\u201373. https:\/\/doi.org\/10.30574\/ijsra.2024.13.2.2342.","journal-title":"Int. J. Sci. Res. Arch"},{"key":"872_CR123","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fmed.2022.820755","volume":"9","author":"L Barbier","year":"2022","unstructured":"Barbier L, Mbuaki A, Simoens S, Declerck P, Vulto AG, Huys I. Regulatory Information and guidance on biosimilars and their use acros s Europe: a call for strengthened One voice messaging. Front Med. 2022;9:9. https:\/\/doi.org\/10.3389\/fmed.2022.820755.","journal-title":"Front. Med"},{"issue":"3","key":"872_CR124","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40267-025-01145-5","volume":"41","author":"MC Raposo","year":"2025","unstructured":"Raposo MC, Feiteira C, Ribeiro MHL. Regulatory and clinical aspects in biosimilar medicines: comparability, extrapolation, interchangeability, and safety. Drugs Ther Perspect. 2025;41(3):111\u201325. https:\/\/doi.org\/10.1007\/s40267-025-01145-5.","journal-title":"Drugs Ther Perspect"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00872-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00872-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00872-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:03:12Z","timestamp":1785798192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00872-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00872-9","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"102"}}